JPMorgan Chase & Co. Increases Position in Corcept Therapeutics Incorporated $CORT

JPMorgan Chase & Co. raised its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 223.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 849,864 shares of the biotechnology company’s stock after acquiring an additional 587,053 shares during the period. JPMorgan Chase & Co. owned approximately 0.81% of Corcept Therapeutics worth $70,632,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CORT. Norges Bank purchased a new stake in shares of Corcept Therapeutics in the second quarter valued at approximately $72,048,000. Epoch Investment Partners Inc. purchased a new position in Corcept Therapeutics during the second quarter worth approximately $56,181,000. Pacer Advisors Inc. boosted its stake in Corcept Therapeutics by 6,796.7% during the third quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock worth $32,459,000 after buying an additional 384,896 shares during the last quarter. Synergy Asset Management LLC grew its holdings in Corcept Therapeutics by 96.1% in the 3rd quarter. Synergy Asset Management LLC now owns 506,856 shares of the biotechnology company’s stock valued at $39,615,000 after buying an additional 248,362 shares in the last quarter. Finally, Brown Capital Management LLC acquired a new stake in shares of Corcept Therapeutics in the 3rd quarter worth $19,950,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

Corcept Therapeutics Price Performance

Corcept Therapeutics stock opened at $36.48 on Wednesday. The company’s 50 day simple moving average is $47.21 and its 200-day simple moving average is $66.45. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.14. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $117.33. The company has a market capitalization of $3.84 billion, a price-to-earnings ratio of 41.46 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 EPS. As a group, equities research analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Truist Financial set a $50.00 price target on shares of Corcept Therapeutics in a research report on Wednesday, December 31st. HC Wainwright decreased their target price on shares of Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Weiss Ratings restated a “hold (c)” rating on shares of Corcept Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a report on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $77.17.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company issued audited Q4 and full‑year 2025 results and an optimistic outlook that management characterized as positive for the business — this messaging likely supports intraday buying interest. Corcept Therapeutics Posts Strong 2025 Results
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to a $900 million – $1.0 billion range; the midpoint sits slightly below some sell‑side consensus, leaving room for mixed analyst reactions and uncertainty about near‑term estimates. FY‑2026 Guidance / Press Release
• Negative Sentiment: Reported Q4 EPS of $0.20 missed consensus ($0.27) and revenue of ~$202.1M missed estimates (~$254.9M). The beat/miss details explain part of today’s volatility and investor caution. Earnings Details / Conference Call
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applicants in a securities class action covering Oct. 31, 2024–Dec. 30, 2025, alleging Corcept failed to disclose FDA concerns about the adequacy of evidence for the relacorilant NDA — this legal overhang is materially negative and has been cited as a driver of a prior ~50% share decline. Representative notices: Robbins LLP and Rosen Law Firm. Robbins LLP Class Action Notice Rosen Law Firm Notice
• Negative Sentiment: Analyst reaction: HC Wainwright cut its price target (reflecting changed expectations post‑NDA/FDA disclosure), adding downward pressure on sentiment. HC Wainwright PT Cut

Insider Transactions at Corcept Therapeutics

In other news, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the completion of the sale, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. The trade was a 32.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Joseph K. Belanoff sold 40,000 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.77, for a total value of $3,190,800.00. Following the completion of the sale, the chief executive officer owned 2,701,370 shares in the company, valued at $215,488,284.90. This represents a 1.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 125,000 shares of company stock valued at $8,301,450. Corporate insiders own 20.50% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.